Amoéba Very convincing results observed by winegrowers

Amoéba announced positive results of its wine-growing trials in France and Europe. Amoéba conducted a series of trials with winegrowers in several major French wine-growing regions. The main objectives of this campaign were to demonstrate the effectiveness of AXPERA, its innovative biological solution, and to validate its reliability in local programmes and practical conditions. We saw results incorporating AXPERA into vineyards' treatment programme that has enabled them to reduce copper input while achieving better protection against mildew than with a standard program. Amoéba confirms that an approval schedule still on track for market launch in 2026. While French winegrowers confirm the effectiveness of AXPERA in the vineyards, the product is simultaneously continuing its regulatory process in the most strategic markets. Conducted as part of Amoéba's partnership with Koppert, these procedures cover vines, vegetable crops and soybeans in Brazil. Regarding the registration dossier submitted to the US EPA, , Amoéba estimates that approval could now come in 1Q26.


We maintain our Buy rating and € 1.5 Target Price.